Objective: Transforming growth factor-b (TGF-b) plays a critical role in cartilage homeostasis and deregulation of its signalling is implicated in osteoarthritis (OA). TGF-b isoforms signal through a pair of transmembrane serine/threonine kinases known as the type I and type II TGF-b receptors. Endoglin is a TGF-b co-receptor that binds TGF-b with high affinity in the presence of the type II TGF-b receptor. We have previously shown that endoglin is expressed in human chondrocytes and that it forms a complex with the TGF-b signalling receptors. However, the functional significance of endoglin expression in chondrocytes is unknown. Our objective was to determine whether endoglin regulates TGF-b/Smad signalling and extracellular matrix (ECM) production in human chondrocytes and whether its expression varies with chondrocyte differentiation state. Method: Endoglin function was determined by overexpression or antisense morpholino/siRNA knockdown of endoglin in human chondrocytes and measuring TGF-b-induced Smad phosphorylation, transcriptional activity and ECM production. Alterations in endoglin expression levels were determined during subculture-induced dedifferentiation of human chondrocytes and in normal vs OA cartilage samples. Results: Endoglin enhances TGF-b1-induced Smad1/5 phosphorylation and inhibits TGF-b1-induced Smad2 phosphorylation, Smad3-driven transcriptional activity and ECM production in human chondrocytes. In addition, the enhancing effect of endoglin siRNA knockdown on TGF-b1-induced Smad3-driven transcription is reversed by ALK1 overexpression. Furthermore, endoglin levels are increased in chondrocytes following subculture-induced dedifferentiation and in OA cartilage as compared to normal cartilage. Conclusion: Together, our results suggest that endoglin regulates the balance between TGF-b/ALK1/ Smad1/5 and ALK5/Smad2/3 signalling and ECM production in human chondrocytes and that endoglin may represent a marker for chondrocyte phenotype.
Introduction
Transforming growth factor-b (TGF-b) is a multifunctional regulator of cartilage repair and homeostasis with critical roles in chondrocyte proliferation, differentiation and extracellular matrix (ECM) production 1e3 . Studies in mice have shown that disruption of TGF-b signalling leads to the development of degenerative joint disease resembling human osteoarthritis (OA) 4, 5 . Furthermore, TGF-b receptor expression and TGF-b signalling are markedly reduced in murine models of OA 6 . Conversely, TGF-b treatment has been reported to result in OA-like lesions in rat knee joints suggesting that excessive TGF-b action may also play a role in OA pathogenesis 7, 8 . Thus, factors that increase or decrease TGFb activity may be important in maintaining chondrocyte phenotype and preventing cartilage diseases such as OA.
TGF-b isoforms (b1, b2, b3) signal through a pair of transmembrane serine/threonine kinases known as the type I (TbRI or activin receptor-like kinase-5; ALK5) and the type II (TbRII) receptors 9 . TGF-b binds TbRII which, in turn, recruits ALK5 resulting in the formation of a heteromeric receptor complex 10, 11 . TbRII is a constitutively active kinase and phosphorylates ALK5 within the TGF-b receptor complex leading to activation of ALK5 kinase activity. The activated ALK5 propagates the TGF-b signal by phosphorylating intracellular Smad2 and Smad3. Besides signalling through the ALK5/Smad2/3 pathway, TGF-b has also been shown to signal through another type I TGF-b receptor named ALK1 leading to phosphorylation of Smad1 and Smad5 12, 13 . Phosphorylated Smad2/3 and phosphorylated Smad1/5 associate with Smad4 and translocate to the nucleus where they interact with various transcriptional coactivators, corepressors and transcription factors to modulate target gene expression 14 .
Endoglin is a TGF-b co-receptor that has been shown to modulate TGF-b signalling in endothelial cells 15, 16 . Endoglin binds TGF-b1 and -b3 with high affinity in the presence of TbRII but does not bind TGF-b2 15, 16 . Although endoglin is not a signalling receptor, it has been shown to associate with the TGF-b signalling receptors (TbRII, ALK1 and ALK5) and to modulate their phosphorylation status as well as downstream Smad-dependent and Smad-independent signalling in endothelial cells 17 . We have previously shown that endoglin is expressed in human chondrocytes and that it forms a heteromeric complex with TbRII and TbRI (ALK1 and ALK5) 18 .
However, the functional significance of endoglin expression in chondrocytes is unknown. Here we show that endoglin enhances TGF-b1-induced Smad1/5 phosphorylation but inhibits TGF-b1-induced Smad2 phosphorylation, Smad3-driven transcriptional activity and ECM protein (type II collagen and PAI-1) expression in human chondrocytes. We also demonstrate that the enhanced TGFb-induced Smad3-driven transcription by endoglin siRNA knockdown is reversed by ALK1 overexpression. Furthermore, we show that endoglin expression is increased in human chondrocytes following subculture-induced dedifferentiation in vitro and in OA cartilage as compared to normal cartilage in vivo. Taken together, our results establish endoglin as a regulator of TGF-b/Smad signalling and ECM production in human chondrocytes and suggest that endoglin may represent a potential marker for chondrocyte dedifferentiation and/or phenotype.
Method

Cell culture
The SV40-immortalized human chondrocyte cell lines, C28/I2 and tsT/AC62, have been described previously 19 . The C28/I2 cell line was developed from chondrocytes isolated from juvenile human costal cartilage and immortalized by retroviral infection of the SV40 large T antigen 20 . The tsT/AC62 cells were developed from chondrocytes isolated from adult human articular cartilage and immortalized by retroviral infection of a temperature-sensitive mutant of SV40 large T antigen that is functional at 32 C but not at 37 C 19 . Primary chondrocytes were isolated from human osteoarthritic articular cartilage obtained intraoperatively from adult arthroplasty specimens or from normal adult cartilage obtained from traumatic open joint injuries with no evidence of degenerate joint disease (normal cartilage, N). All procedures were approved by the Research Ethics Board of the McGill University Health Center and all cartilage samples were obtained with informed consent. The cartilage was rinsed with cold phosphate buffered saline (PBS), minced and then incubated for 1 h at 37 C with 1 mg/ml Pronase followed by overnight digestion at 37 C with 1 mg/ml collagenase.
The suspension was passed through a 70 mm cell sieve and chondrocytes were collected by 5 min centrifugation, washed with PBS and plated at a density of 2.5 Â 10 5 cells/cm 2 . Alternatively, chondrocyte cultures were established by outgrowth of explants as described previously 21 . All cells were cultured in DMEM/F12 containing 10% fetal bovine serum and antibiotics and maintained at 37 C in a humidified incubator under 5% CO 2 /air (Supplementary information for details).
The 3-dimensional (3-D) alginate culture system for chondrocyte redifferentiation has been described previously 19, 20 . Briefly, chondrocytes (4 Â 10 6 cells/ml) were suspended in a 1.2% alginate solution and passed drop-wise through a 25-gauge needle into a 102 mM CaCl 2 solution resulting in the formation of alginate beads. The beads were washed with 0.15 M NaCl and transferred to culture flasks with serum-containing media. The alginate beads were cultured for 21 days and the media changed every third day. Alginate beads were depolymerised with 55 mM sodium citrate/ 0.15 M NaCl and the recovered chondrocytes washed in PBS, resuspended in serum-containing media, plated (2.5 Â 10 5 cells/ cm 2 ) and grown to confluence. Subculture-induced dedifferentiation was performed by serially passaging confluent chondrocytes at a 1:2 split ratio for up to 12 passages. Cells at passage 1e2 are designated as 'early passage' and cells at passage 10e12 are designated as 'late passage'. Chondrocyte morphology was visualized by phase contrast microscopy and images were captured with a digital camera.
Affinity labelling
Affinity labelling was performed as described previously 13 .
Briefly 
Transfections
Endoglin overexpression: Chondrocytes were transiently transfected with endoglin or its empty vector (EV) using Lipofectamine 2000 according to the manufacturers' instructions. Endoglin knockdown: Chondrocytes were transfected with endoglin-specific antisense morpholinos or control morpholinos using i-PEI transfection reagent according to the manufacturers' instructions. Alternatively, chondrocytes were transfected with endoglinspecific siRNA, ALK1-specific siRNA or control siRNA as described previously 22 .
Western blot analysis
Chondrocytes transfected with (1) endoglin or EV, (2) endoglinspecific or control morpholinos or (3) endoglin-specific siRNA, ALK1-specific siRNA or control siRNA were grown overnight in serum-containing media. Chondrocytes were washed with PBS, serum-starved for 3 h and then treated for 45 min or 24 h with 0e100 pM TGF-b1. Cell lysates were prepared in RIPA buffer (Supplementary information for details). Samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked with Trisebuffered salineeTween 20 (Supplementary information for details) and incubated overnight at 4 C with the indicated primary antibodies (Supplementary Table  1 for antibody information). Membranes were washed with TBST and incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody. Detection was performed using the enhanced chemiluminescence (ECL) system.
Luciferase assays
C28/I2 cells were transfected with (1) Eg or EV plasmids or (2) endoglin-specific siRNA or control siRNA. In some experiments, endoglin-specific siRNA and control siRNA transfected cells were co-transfected with wild-type (WT) ALK1, constitutively active ALK1 (QD) or EV. Cells were co-transfected with Smad3-responsive CAGA 12 -lux 23 or Smad2/3-responsive 3TP-lux 24 luciferase reporter constructs. All cells were co-transfected with pCMV-b-galactosidase. Cells were then treated for 24 h with 0e100 pM of TGF-b1 or TGF-b2 under serum-free conditions. Cell lysates were prepared and analyzed for luciferase and b-galactosidase activity as described previously 13 . The data are presented as a fold-change in luciferase activity from control (absence of ligand addition and/or transfection with control siRNA/EV alone).
Statistical analysis
Means calculated from replicates of three or more independent experiments were used for statistical analysis. Differences between the means were compared using Analysis of Variance (ANOVA) followed by post hoc pair-wise comparision using Bonferroni t-test (Systat 11.0; Systat, Chicago, IL).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from chondrocytes and reverse transcribed using (MMLV)-RT and oligo-dT primer. PCR was performed using human endoglin 25 and human GAPDH primers 26 and Taq polymerase (Supplementary information for details). PCR products were resolved by agarose gel electrophoresis and visualized by ethidium bromide staining 13 .
Cartilage extraction
Total protein was extracted from human articular cartilage as described previously 27 . Briefly, cartilage tissue was pulverized under liquid nitrogen using a biopulverizer (Biospec Products Inc., Bartlesville, OK) and then homogenized in GuCl extraction buffer [4 M GuCl/50 mM Tris, pH 7.5 and 1 mM ethylenediaminetetraacetic acid (EDTA)]. Samples were vortexed at 4 C for 30 min, centrifuged at 15,000Âg for 10 min at 4 C and the supernatants were collected and precipitated with 5 vol 100% ethanol at À20 C. Pellets were washed with 75% ethanol, dried, and resuspended in 8 M urea. Samples containing equivalent amounts of protein were analyzed by Western blot using an anti-endoglin antibody. Membranes were stained with Ponceau to confirm equal protein loading.
Immunohistochemistry
Cartilage tissue was fixed in a periodate-lysine-paraformaldehyde solution 28 and embedded in a solution containing two parts 20% sucrose phosphate buffer to one part O.C.T. embedding medium (Tissu-Tek, Miles, USA). Cryostat sections (8 mm) were obtained, fixed in 4% paraformaldehyde, washed in PBS and treated with chondroitinase ABC for 1 h at 37 C. The sections were washed in PBS, blocked for 1 h at room temperature with 5% normal goat serum and then incubated overnight at 4 C with anti-endoglin (Dako, SN6h, 1:100) antibody. Sections were washed in PBS and incubated at room temperature for 30 min with a HRP-conjugated anti-mouse secondary antibody. Immune complexes were detected using the Vectastain ABC kit according to the manufacturers' instructions (Vector Laboratories, Burlington, ON).
Results
Endoglin inhibits TGF-b1-induced Smad2 phosphorylation and enhances TGF-b1-induced Smad1/5 phosphorylation in human chondrocytes
The ability of endoglin to regulate TGF-b/Smad signalling in human chondrocytes was examined by blocking endoglin expression in primary human articular chondrocytes using antisense morpholinos and measuring TGF-b1-induced Smad2 phosphorylation. Fig. 1(A) demonstrates that blocking endoglin expression is associated with enhanced TGF-b1-induced Smad2 phosphorylation Western blot analysis also demonstrated that chondrocytes transfected with endoglin-specific morpholinos display a marked reduction in endoglin protein levels as compared to control morpholino transfected cells (data not shown).
The effect of blocking endoglin expression on TGF-b1-induced Smad2 phosphorylation was also examined using a siRNA-based approach. 
Endoglin inhibits TGF-b1-induced Smad3-driven transcriptional activity in human chondrocytes
The effect of endoglin on Smad3-driven signalling was examined using the Smad3-responsive CAGA 12 -lux and Smad2/ 3-responsive 3TP-lux luciferase reporter constructs in C28/I2 cells. Results shown in Table I demonstrate that endoglin siRNA transfection leads to a significant increase (P ¼ 0.006) in TGF-b1-induced CAGA 12 -lux activity as compared to control siRNA transfection. Similarly, endoglin siRNA treatment results in increased TGF-b1-induced 3TP-lux activity ( Supplementary  Fig. 1 ). Interestingly, endoglin siRNA transfection also leads to enhanced TGF-b2-induced CAGA 12 -lux activity in these cells ( Supplementary Fig. 2 ), suggesting that endoglin regulates TGF-b signalling in a TGF-b isoform-independent manner in human chondrocytes. We also found that overexpression of endoglin inhibited TGF-b1-induced CAGA 12 -lux activity ( Supplementary Fig. 3 ), supporting the results obtained with siRNA.
We next examined whether the stimulatory effect of endoglin siRNA knockdown on TGF-b1-induced Smad3-driven transcriptional activity could be reversed by ALK1 overexpression. Importantly, co-transfection of WT or constitutively active (QD) ALK1 leads to a significant reduction in the stimulatory effect of endoglin siRNA knockdown on TGF-b1-induced CAGA 12 -lux activity [Fig 3(A) , P ¼ 0.006 and 0.002, respectively]. Expression levels of endoglin and ALK1 proteins are depicted in Fig. 3(B) and (C), respectively.
Endoglin inhibits TGF-b1-induced ECM production in human chondrocytes
Our previous results have shown that TGF-b1 stimulates type II collagen and PAI-1 protein production in human chondrocytes 13 .
The role of endoglin in regulating ECM production was first examined in primary human articular chondrocytes. 
Endoglin expression is increased following subculture-induced dedifferentiation
The effects of subculture-induced dedifferentiation on endoglin expression were examined in early and late passage primary human articular chondrocytes. Fig. 5(A) (top panel) shows that endoglin protein levels are higher in late passage as compared to early passage chondrocytes. Type II collagen protein levels are lower in late passage as compared to early passage chondrocytes [ Fig. 5(A) , middle panel] consistent with the process of chondrocyte dedifferentiation 30, 31 . Reprobing the membrane with an anti-STAT3 antibody confirms that equal amounts of protein are loaded in each lane [ Fig. 5(A), bottom panel] .
Endoglin expression in early and late passage primary articular chondrocytes was also examined at the mRNA level. RT-PCR analysis performed on total RNA extracted from early and late passage chondrocytes indicates that endoglin mRNA levels are higher in late passage as compared to early passage chondrocytes 
Endoglin protein expression in OA and normal cartilage
We next examined endoglin protein expression in vivo in cartilage samples obtained from the knee of OA patients and normal controls. Cartilage protein was extracted as described in the Method section and analyzed by Western blot using an anti-endoglin antibody. Results shown in Fig. 7(A) demonstrate that endoglin protein levels are higher in OA as compared to normal cartilage. Ponceau staining of the membrane confirms that equal amounts of protein were loaded in each lane. Similar results were obtained when comparing endoglin protein levels in three different pairs of OA and normal cartilage samples (data not shown). Endoglin expression was also examined in human OA and normal cartilage by immunohistochemistry using an anti-endoglin (SN6h, Dako) antibody. Fig. 7(B) demonstrates that OA cartilage displays enhanced staining for endoglin as compared to normal cartilage. No staining was detected when the primary antibody was omitted in parallel experiments (data not shown).
Discussion
TGF-b is a pleiotropic cytokine that plays a critical role in maintaining cartilage homeostasis 6, 32 . Although deregulation of TGF-b signalling has been implicated in cartilage diseases such as OA 6, 32 , the factors that regulate TGF-b signalling in normal or diseased human chondrocytes are unclear. We have previously shown that human chondrocytes express several different TGF-b receptors including two isoforms of TbRII (RII and RIIB), two different TbRIs (ALK5 and ALK1) and the TGF-b co-receptors endoglin and betaglycan 13, 18, 33 . We have shown that endoglin forms a heteromeric complex with TbRII and TbRI (ALK5 and ALK1) in human chondrocytes 13, 18 as has been demonstrated for endoglin in endothelial cells 11,34e37 . However, the functional significance of endoglin expression in human chondrocytes has not been examined. Here we show that endoglin enhances TGF-b1-induced Smad1/5 phosphorylation but inhibits TGF-b1-induced Smad2 phosphorylation, Smad3-driven (CAGA 12 -lux and 3TP-lux) transcriptional activity and type II collagen and PAI-1 protein expression in human chondrocytes. Moreover, we present evidence that endoglin expression is increased in human chondrocytes following subculture-induced dedifferentiation in vitro and that endoglin expression levels are increased in human OA cartilage as compared to normal cartilage in vivo. Collectively, our results establish endoglin as a regulator of TGF-b signalling and ECM protein production with opposing effects on the ALK1/Smad1/5 and ALK5/ Smad2/3 pathways in human chondrocytes and suggest that endoglin may represent a potential marker for chondrocyte dedifferentiation or the loss of chondrogenic phenotype.
Endoglin is a TGF-b co-receptor that has been shown to regulate TGF-b signalling in endothelial cells 12, 17, 38 . Our present results
show that endoglin enhances TGF-b1-induced Smad1/5 phosphorylation but decreases TGF-b1-mediated Smad2 phosphorylation in human chondrocytes. In comparison, other studies report conflicting data on the role of endoglin in regulating TGF-b-mediated Smad1/5 and Smad2 signalling in different cell types. For example, ectopic expression of endoglin in rat myofibroblasts was reported to increase phosphorylation (and total levels) of Smad2 39 whereas another study using ectopic expression of endoglin in rat myofibroblasts reported no significant effect on TGF-b-induced phosphorylation of Smad1 or Smad2 40 . Conversely, studies using endoglin-null mouse embryonic endothelial cells reported that endoglin promotes TGF-b-mediated Smad1/5 signalling 36, 41 whereas another study using endoglin siRNA knockdown in human bone marrow stromal cells reported that endoglin acts as a positive regulator of both ALK1-induced Smad1 activation and ALK5-induced Smad2 activation 42 . Taken together, these studies suggest that endoglin differentially regulates TGF-b signalling via ALK1/Smad1/5 and ALK5/Smad2 depending on cell-type and cellular context. Our results suggest that endoglin differentially regulates TGF-b/Smad signalling in human chondrocytes by promoting TGF-b signalling through the ALK1/Smad1/5 pathway and decreasing signalling through the ALK5/Smad2/3 pathway.
Our previous work has demonstrated that ALK1 inhibits TGF-b/ALK5-dependent Smad3-driven transcriptional activity and ECM production in human chondrocytes 13 . Our present results indicate that endoglin also inhibits TGF-b1/ALK5-induced Smad3-driven transcriptional activity and ECM production in human chondrocytes. Because we have shown that endoglin interacts with ALK1 in human chondrocytes 13 and that others have shown endoglin to interact with, and promote signalling through, ALK1 in endothelial cells to inhibit ALK5 signalling 36 , it is plausible that endoglin regulates TGF-b/ALK5 signalling through a similar mechanism in human chondrocytes. Our results showing that endoglin promotes TGF-b1/ALK1 signalling (i.e., Smad1/5 phosphorylation) and that overexpression of ALK1 can reverse the stimulatory effect of endoglin siRNA knockdown on TGF-b1-induced CAGA 12 -lux activity are consistent with this notion. Whether endoglin inhibits TGF-b/ALK5/Smad2/3 signalling by promoting the TGF-b/ALK1/Smad1/5 pathway or by regulating other pathways remains to be determined. Importantly, our finding that endoglin inhibits TGF-b-induced Smad3-driven transcription provides further evidence for endoglin's role in inhibiting TGF-b-mediated ALK5/Smad2/3 signalling in human chondrocytes. Primary human articular chondrocytes maintain a rounded, polygonal morphology in monolayer culture but undergo a progressive change to an elongated fibroblast-like morphology over time, particularly after subculture 43 . Accompanying these morphological changes is the loss of the chondrogenic (differentiated) phenotype or 'chondrocyte dedifferentiation' which is characterized by a decrease in type II collagen expression 43 . Our results demonstrate that primary human articular chondrocytes and tsT/ AC62 cells display such changes in morphology and reduction in type II collagen expression following serial passage in monolayer suggesting that these cells undergo subculture-induced dedifferentiation. Human costal chondrocytes (C28/I2) also show a decrease in type II collagen expression after serial passage in monolayer although morphological changes were not observed in these cells (data not shown). Importantly, our results showing that endoglin protein levels are higher in late passage as compared to early passage chondrocytes suggest that endoglin expression is increased following subculture-induced dedifferentiation. The increased endoglin protein expression in late passage chondrocytes is mirrored by an increase in endoglin mRNA expression indicating that the mechanism of its up-regulation involves an increase in endoglin gene expression and/or an increase in endoglin mRNA stability. Our results are consistent with a previous report identifying endoglin as one of many cell surface molecules upregulated in primary articular chondrocytes during cell expansion in monolayer 44 . Thus, our results suggest that endoglin may represent a novel marker for chondrocyte dedifferentiation and/or the loss of normal 'differentiated' chondrocyte phenotype. Factors that regulate TGF-b signalling in normal and 'phenotypically altered' chondrocytes are ill-defined. A previous study has shown that ALK1 mRNA levels are increased during in vitro expansion of primary human articular chondrocytes 45 and a more recent study has reported an increase in the ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in OA in humans and mice 46 . Our results showing that endoglin levels are increased in human chondrocytes following subculture-induced dedifferentiation in vitro and in human OA cartilage as compared to normal cartilage in vivo extend these findings and raise the possibility that increased expression of endoglin and ALK1 together leads to a shift in TGF-b signalling away from the ALK5/Smad2/3 pathway in favour of ALK1/Smad1/5 pathway. Further studies using increased numbers of age-, sex-and gender-matched OA and normal human cartilage samples will be needed to confirm these findings. In conclusion, our results establish endoglin as a regulator of TGF-b signalling and ECM protein production with opposing effects on the ALK1/Smad1/5 and ALK5/Smad2/3 pathways in human chondrocytes and suggest that endoglin may represent a potential marker for chondrocyte dedifferentiation or loss of chondrogenic phenotype. Delineation of the precise mechanism by which endoglin may regulate the balance of ALK1 and ALK5 signalling in human chondrocytes will be a fruitful avenue for future studies.
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